UniQure drops plans to seek FDA approval for Glybera

Published: 2 December 2015

UniQure have abandoned their ambition to win FDA approval for their gene therapy, Glybera. The decision to no longer seek approval to market their $1.2 million-per-course gene therapy in the USA came after the FDA made the request to see data from two clinical trials of the lipoprotein lipase deficiency (LPLD) therapy. As the product […]

Read now